Basic Information | Post buying leads | Suppliers |
Name |
TIAPRIDE HYDROCHLORIDE |
EINECS | 256-908-4 |
CAS No. | 51012-33-0 | Density | 1.15 g/cm3 |
PSA | 84.09000 | LogP | 3.44400 |
Solubility | N/A | Melting Point |
approximate 200℃ (dec.) |
Formula | C15H24 N2 O4 S . Cl H | Boiling Point | 498.1 °C at 760 mmHg |
Molecular Weight | 364.894 | Flash Point | 255.1 °C |
Transport Information | N/A | Appearance | N/A |
Safety | Poison by ingestion, intravenous, and intraperitoneal routes. Moderately toxic by subcutaneous route. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of SOx, NOx, and HCl. | Risk Codes | N/A |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
Benzamide,N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)-, monohydrochloride(9CI); Gramalil; Italprid; Luxoben; Sereprile; Tiapridal; Tiapridehydrochloride; Tiapridex |
UPAC Name: N-(2-diethylaminoethyl)-2-methoxy-5-methylsulfonylbenzamide hydrochloride (51012-33-0)
SynonymsTtiapride hydrochloride ; N-[2-(diethylamino)ethyl]-5-[methyl-sulfonyl]-o-anisamide hydrochloride ; N-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)benzamidehydrochloride ; N-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)-benzamidmonohydroch ; N-(2-(diethylamino)ethyl)-2-methoxy-5-(methylsulfonyl)-benzamidmonohydrochloride ; N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulphonyl)benzamide monohydrochloride ; TiapridHCl;Tiapridhydrochlorid
CAS: 51012-33-0
MF: C15H25ClN2O4S
MW: 364.89
MS:
EINECS: 256-908-4
Mol File: 51012-33-0.mol
Flash Point: 255.1 °C
Enthalpy of Vaporization: 76.63 kJ/mol
Boiling Point: 498.1 °C at 760 mmHg
Vapour Pressure: 4.65E-10 mmHg at 25°C
Storage temp: StoreTiapride hydrochloride (51012-33-0) at 2-8°C.
Tiapride hydrochloride (51012-33-0)is antipsychotics.
Tiapride hydrochloride (51012-33-0)is prepared by reacting 2-methoxy-5-methylsulfonylbenzoic acid (I) with isobutyl chloroformate (A) in dioxane to give the corresponding anhydride (II), which is finally condensed with N,N-diethylethylenediamine (B).
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
dog | LD50 | oral | 240mg/kg (240mg/kg) | sense organs and special senses: mydriasis (pupillary dilation): eye | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
mouse | LD50 | intraperitoneal | 336mg/kg (336mg/kg) | behavioral: altered sleep time (including change in righting reflex) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
mouse | LD50 | intravenous | 189mg/kg (189mg/kg) | behavioral: altered sleep time (including change in righting reflex) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
mouse | LD50 | oral | 1340mg/kg (1340mg/kg) | behavioral: altered sleep time (including change in righting reflex) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
mouse | LD50 | subcutaneous | 755mg/kg (755mg/kg) | behavioral: altered sleep time (including change in righting reflex) | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
rat | LD50 | intraperitoneal | 421mg/kg (421mg/kg) | sense organs and special senses: ptosis: eye | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
rat | LD50 | intravenous | 254mg/kg (254mg/kg) | sense organs and special senses: ptosis: eye | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
rat | LD50 | oral | 4840mg/kg (4840mg/kg) | sense organs and special senses: ptosis: eye | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
rat | LD50 | subcutaneous | 1130mg/kg (1130mg/kg) | sense organs and special senses: ptosis: eye | Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 1933, 1985. |
WGK Germany: 2
RTECS: CV4203800